Quantum BioPharma is trading at $3.64 (+5.20%) after the FDA approved its Investigational New Drug application for Lucid-MS on August 10, 2026, allowing the multiple sclerosis treatment to advance into Phase 2 development.
- Trial start-up activities, including site selection, are underway
- Patient enrollment and drug administration are expected to begin as quickly as possible
- Trading context: live market movement at 10:06 a.m. EST; volume data unavailable